Ciltacabtagene autoleucel (Carvykti®) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||11/04/2022|
|Rapid review completed||12/05/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cilta-cel (ciltacabtagene autoleucel) compared with the current standard-of-care.|